Quick Answer
Xenon Pharmaceuticals Inc. reported Operating Income of -$373.07 million for fiscal year 2025.
Xenon Pharmaceuticals Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$373.07M | -33.6% |
| 2024 | -$279.30M | -30.5% |
| 2023 | -$214.05M | -65.7% |
| 2022 | -$129.14M | -63.5% |
| 2021 | -$78.99M | -152.4% |
| 2020 | -$31.30M | +26.9% |
| 2019 | -$42.82M | -12.6% |
| 2018 | -$38.04M | -16.8% |
| 2017 | -$32.58M | -31.3% |
| 2016 | -$24.82M | -165.1% |
| 2015 | -$9.36M | -184.3% |
| 2014 | $11.11M | +14.4% |
| 2013 | $9.71M | +408.0% |
| 2012 | -$3.15M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$96.34M | -30.8% | -2.2% |
| June 30, 2025 | -$94.23M | -36.4% | -29.5% |
| March 31, 2025 | -$72.74M | -23.2% | +1.3% |
| September 30, 2024 | -$73.68M | -32.3% | -6.6% |
| June 30, 2024 | -$69.10M | -24.2% | -17.0% |
| March 31, 2024 | -$59.04M | -20.4% | -6.0% |
| September 30, 2023 | -$55.68M | -46.0% | -0.1% |
| June 30, 2023 | -$55.62M | -83.5% | -13.4% |
- Xenon Pharmaceuticals Inc. showed a decrease of -33.6% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, Xenon Pharmaceuticals Inc.’s operating income has declined by 11732.2% (from -$3.15 million to -$373.07 million).
- The most recent figure is from Xenon Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: